Intellia Therapeutics (NTLA) News Today $12.12 +0.64 (+5.54%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NTLA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 5.7% - Here's What Happened3 hours ago | marketbeat.comGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (NTLA)Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.July 15 at 4:27 PM | marketbeat.comNTLA - Intellia Therapeutics Inc Trailing Returns - MorningstarJuly 12, 2025 | morningstar.comMMove Over, Magnificent 7: The Frontier 7 Will Redefine Our FutureJuly 10, 2025 | 247wallst.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.1% - Should You Buy?July 8, 2025 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 7, 2025 | globenewswire.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Eliana Clark Sells 1,022 SharesJuly 4, 2025 | insidertrades.comIntellia Therapeutics Inc. Advanced Charts | NTLA | Barron'sJuly 4, 2025 | barrons.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 4, 2025 | marketbeat.comCitizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z DataJuly 3, 2025 | msn.comInsider Selling: Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $10,036.04 in StockJuly 3, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 2,503 SharesJuly 3, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Director Sells $14,278.81 in StockJuly 2, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.8% - Here's WhyJuly 2, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 29, 2025 | marketbeat.comCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - NasdaqJune 27, 2025 | nasdaq.comNTLA - Intellia Therapeutics Inc Chart - MorningstarJune 26, 2025 | morningstar.comMIntellia Therapeutics, Inc. (NTLA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNTLA Intellia Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comWill Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?June 21, 2025 | finance.yahoo.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4% - What's Next?June 20, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside PotentialJune 19, 2025 | finance.yahoo.comWedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)June 18, 2025 | theglobeandmail.comIntellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside PotentialJune 17, 2025 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Up - Here's WhyJune 17, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives Neutral Rating from WedbushJune 16, 2025 | marketbeat.com6NTLA : Assessing Intellia Therapeutics: Insights From 9 Financial...June 16, 2025 | benzinga.comIntellia Therapeutics' (NTLA) Buy Rating Reaffirmed at HC WainwrightJune 16, 2025 | marketbeat.comIntellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology CongressJune 15, 2025 | globenewswire.comBrokers Issue Forecasts for NTLA FY2026 EarningsJune 10, 2025 | marketbeat.comIntellia Therapeutics Inc.June 9, 2025 | barrons.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 8.7% - Should You Buy?June 6, 2025 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Wellington Management Group LLPJune 4, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from AnalystsJune 4, 2025 | marketbeat.comCanaccord Genuity Group Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock PriceJune 3, 2025 | marketbeat.comNuveen Asset Management LLC Decreases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)June 3, 2025 | marketbeat.comEvercore ISI Sticks to Its Buy Rating for Intellia Therapeutics (NTLA)June 1, 2025 | theglobeandmail.comSquarepoint Ops LLC Has $1.18 Million Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)June 1, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 5.6% - Here's What HappenedMay 31, 2025 | marketbeat.comSA analyst downgrades: PLTR, PSTG, NTLA, ARWRMay 30, 2025 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Shares Up 4.7% - Here's What HappenedMay 30, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next?May 30, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Receives "Buy" Rating from HC WainwrightMay 30, 2025 | marketbeat.comIntellia: Heart Disease Safety Setback Triggers Selloff - Caution AdvisedMay 29, 2025 | seekingalpha.comIntellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The DipMay 29, 2025 | msn.comIntellia Shares Drop 19% After Safety Signal Emerges in Phase 3 TrialMay 29, 2025 | msn.comDemystifying Intellia Therapeutics: Insights From 9 Analyst ReviewsMay 29, 2025 | benzinga.comIntellia stock tumbles on safety concernsMay 29, 2025 | finance.yahoo.comIntellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On CourseMay 29, 2025 | benzinga.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.480.97▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼512▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beam Therapeutics News CRISPR Therapeutics News Editas Medicine News Vaxcyte News Cytokinetics News Metsera News ADMA Biologics News Krystal Biotech News Akero Therapeutics News Avidity Biosciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
